A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA

Inclusion Criteria: * Male or female subjects 1 to 17 years of age with assent to participation and his/her parent or guardian is willing and able to sign the informed consent approved by the Independent Review Board / Ethics Committee. * Screening TSAT \< 20% * Screening Hemoglobin \< 11 g/dL * For subjects who are receiving an erythropoietin stimulating agent (ESA): stable ESA therapy (+/- 20% of current dose) for \> 8 weeks prior to the qualifying screening visit and no ESA dosing or product changes anticipated for the length of the trial Exclusion Criteria: * Known hypersensitivity reaction to any component of Ferric Carboxymaltose. * Subject previously randomized and treated in this study or any other clinical study of Ferric Carboxymaltose (FCM or VIT-45). * Body mass index (BMI) ≤ 5th percentile for age (see APPENDIX 2) * Male or Female subject 1 year of age weighing \< 12kg. * History of acquired iron overload, hemochromatosis or other iron accumulation disorders. * Chronic kidney disease subjects on hemodialysis. * Screening Ferritin level \> 300ng/mL * Subjects with significant severe diseases of the liver, hemopoietic system, cardiovascular system, psychiatric disorder or other conditions which on the opinion of the investigator may place a subject at added risk. * Any active infection. * Known positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with evidence of active hepatitis. * Known positive HIV-1/HIV-2 antibodies (anti-HIV). * Anemia d…